載入中
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
前收盤價
US$1.93
−US$0.02 · -1.03%
盤中時間採用ET。市場資料可能有所延遲。
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
日內區間
目前US$1.93
52週區間
目前US$1.93
盤中時間採用ET。市場資料可能有所延遲。
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
日內區間
目前US$1.93
52週區間
目前US$1.93
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.43億 USD | 9720.3萬 USD | 5542.4萬 USD | 3930萬 USD | 3249.4萬 USD |
| 銷售、一般及管理費用 | 2956.7萬 USD | 2793.8萬 USD | 1923.6萬 USD | 1483.9萬 USD | 1381.9萬 USD |
| 營業費用 | 1.72億 USD | 1.25億 USD | 7466萬 USD | 5413.9萬 USD | 4631.3萬 USD |
| 利息收入 | 603.1萬 USD | 1002.5萬 USD | 698.5萬 USD | 116.4萬 USD | 2.4萬 USD |
| 利息支出 | 200.4萬 USD | 74.8萬 USD | — | — | — |
| 折舊和攤銷 | 164.6萬 USD | 171.1萬 USD | 142.6萬 USD | 117.8萬 USD | 73.3萬 USD |
| 營業利益 | −1.72億 USD | −1.25億 USD | −7466萬 USD | −5413.9萬 USD | −4631.3萬 USD |
| 淨利 | −1.68億 USD | −1.16億 USD | −6767.5萬 USD | −5297.5萬 USD | −4628.9萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1621.92萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI977.14萬0.10%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM836.65萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF591.18萬0.01%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM345.1萬0.05%64.1億 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB221.81萬0.02%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO201.34萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO150.5萬0.01%139.17億 USD0.24%US$356.78+0.94%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
